 |
424 Diseases |  |
807 Trials |
|
807 Trials |  |
14372 News |  |
| «12...345678910111213...235236» |
- || leucovorin calcium / Generic mfg., sulphadiazine / Generic mfg., pyrimethamine / Generic mfg.
Clinical data, Observational data, Journal: REIV-TOXO Project: Results from a Spanish cohort of congenital toxoplasmosis (2015-2022). The beneficial effects of prenatal treatment on clinical outcomes of infected newborns. (Pubmed Central) - Nov 1, 2024
While diagnosis based only on neonatal assessment misses a significant number of CT cases, prenatal screening allows treatment to be started during pregnancy, with better clinical outcomes at birth and during follow-up. REIV-TOXO provides valuable information about CT in Spain, highlighting the need for universal maternal screening.
- | Opdivo (nivolumab) / BMS
Journal, FDG PET: FDG PET Images of Pseudoprogression After Nivolumab-FOLFOX Chemotherapy in a Gastric Cancer Patient. (Pubmed Central) - Nov 1, 2024
The pathology of the right neck node confirmed reactive lymph node hyperplasia without evidence of malignancy, suggesting pseudoprogression after immunotherapy. It is worthwhile to report these PET image patterns, as they could significantly influence clinical decision-making.
- | Onivyde (nanoliposomal irinotecan) / Servier, Ipsen
New P2 trial: NALIRIFOX Combined With PD-1 Sequential Radiotherapy Versus NALIRIFOX as Conversion Therapy of Locally Advanced Pancreatic Cancer (clinicaltrials.gov) - Nov 1, 2024
P2, N=120, Not yet recruiting, Sponsor: The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
- || TTX-080 / Tizona Therap
Trial completion date, Trial primary completion date, Monotherapy: TTX-080-001: TTX-080 HLA-G Antagonist in Subjects with Advanced Cancers (clinicaltrials.gov) - Oct 31, 2024
P1, N=240, Active, not recruiting, Sponsor: Tizona Therapeutics, Inc
It is worthwhile to report these PET image patterns, as they could significantly influence clinical decision-making. Trial completion date: Jun 2024 --> Jun 2027 | Trial primary completion date: Dec 2023 --> Jun 2024
- || monalizumab (IPH2201) / AstraZeneca, Innate, Imfinzi (durvalumab) / AstraZeneca
Trial completion date: A Study of Durvalumab (MEDI4736) and Monalizumab in Solid Tumors (clinicaltrials.gov) - Oct 31, 2024
P1/2, N=383, Active, not recruiting, Sponsor: MedImmune LLC
Trial completion date: Jun 2024 --> Jun 2027 | Trial primary completion date: Dec 2023 --> Jun 2024 Trial completion date: Sep 2024 --> Sep 2025
- | 5-fluorouracil / Generic mfg.
Retrospective data, Journal: Adjuvant Chemotherapy Duration and Disease-Free Survival in Low-Risk Stage III Colon Cancer with N1a-b and N1c Disease: Insights from a Single-Center Retrospective Analysis. (Pubmed Central) - Oct 31, 2024
Trial completion date: Sep 2024 --> Sep 2025 Our study indicates that shorter duration of adjuvant chemotherapy is associated with worse survival and 6-month chemotherapy is recommended for patients with pT1-3 and N1c disease.
- | Journal: FOLFOXIRI for First-Line Treatment of Unresectable Colorectal Cancer with Liver Metastases in a Resource-Limited Setting. (Pubmed Central) - Oct 31, 2024
P=N/A
FOLFOXIRI improves the response rates, R0/R1 resection rates, and survivals for patients with CRC liver metastases. Future research is necessary to improve the prognosis of patients while minimizing toxicities.
- || onvansertib (PCM-075) / Cardiff Oncology
P2 data, Journal, Combination therapy, Metastases: Onvansertib in Combination With Chemotherapy and Bevacizumab in Second-Line Treatment of KRAS-Mutant Metastatic Colorectal Cancer: A Single-Arm, Phase II Trial. (Pubmed Central) - Oct 30, 2024
P2
Onvansertib in combination with FOLFIRI + bevacizumab showed significant activity in the second-line treatment of patients with KRAS-mutant mCRC, particularly in patients with no prior bevacizumab treatment. These findings led to the evaluation of the combination in the first-line setting (ClinicalTrails.gov identifier: NCT06106308).
- || Keytruda (pembrolizumab) / Merck (MSD)
Review, Journal, Metastases: Vogt-Koyanagi-Harada-Like Uveitis Secondary to Pembrolizumab in Metastatic Gastric Cancer: A Case Report and Review of the Literature. (Pubmed Central) - Oct 30, 2024
She continues on trastuzumab maintenance, and most recent imaging shows no evidence of disease. Oncologists should be aware of VKH-like disease as a possible immune-related adverse event and seek urgent ophthalmologic consultation when such symptoms arise.
- | Blincyto (blinatumomab) / Astellas, Amgen, Opdivo (nivolumab) / BMS
Enrollment change, Checkpoint inhibition: AALL1821: A Study to Compare Blinatumomab Alone to Blinatumomab With Nivolumab in Patients Diagnosed With First Relapse B-Cell Acute Lymphoblastic Leukemia (B-ALL) (clinicaltrials.gov) - Oct 30, 2024
P2, N=300, Suspended, Sponsor: National Cancer Institute (NCI)
Oncologists should be aware of VKH-like disease as a possible immune-related adverse event and seek urgent ophthalmologic consultation when such symptoms arise. N=550 --> 300
- ||| Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
P3 data, Journal, Metastases: Devimistat (CPI-613) With Modified Fluorouarcil, Oxaliplatin, Irinotecan, and Leucovorin (FFX) Versus FFX for Patients With Metastatic Adenocarcinoma of the Pancreas: The Phase III AVENGER 500 Study. (Pubmed Central) - Oct 29, 2024
P3
Devimistat in combination with mFFX did not improve long- and short-term mPC patient outcomes compared with standard FFX. There were no new toxicity signals with the addition of devimistat.
- || Review, Journal, Checkpoint inhibition: Immune checkpoint inhibitor therapy for primary neuroendocrine carcinoma of the gallbladder: A case report and literature review. (Pubmed Central) - Oct 29, 2024
There were no new toxicity signals with the addition of devimistat. The use of immune checkpoint inhibitors may become an effective tool in the treatment of neuroendocrine carcinoma of the gallbladder.
- | 5-fluorouracil / Generic mfg.
Journal, PD(L)-1 Biomarker, IO biomarker: Antagonistic roles of cGAS/STING signaling in colorectal cancer chemotherapy. (Pubmed Central) - Oct 29, 2024
FOLFOX, composed of 5-FU, oxaliplatin and leucovorin, is a first line chemotherapy regimen for colorectal cancer (CRC) treatment...Tumor studies in syngeneic immune competent mice demonstrate that the combination of 5-FU/oxaliplatin and anti-PD-1 significantly reduced tumor growth of colon cancer cells compared to 5-FU/oxaliplatin treatment alone. Taken together, our studies have identified a unique pathway leading to chemoresistance and provide a rationale to combine FOLFOX with anti-PD-1/PD-L1 as an effective CRC treatment.
- | Teysuno (gimeracil/oteracil/tegafur) / Nordic Group, Otsuka, Focus V (anlotinib) / Advenchen, Sino Biopharm
New P2/3 trial, Metastases: Anlotinib Plus Nab-Paclitaxels and S-1 for Patients with Advanced Biliary Tract Cancer As Second-Line Treatment (clinicaltrials.gov) - Oct 29, 2024
P2/3, N=206, Not yet recruiting, Sponsor: Sun Yat-sen University
- |||||||||| Rybrevant (amivantamab-vmjw) / J&J
New P3 trial, Metastases: OrigAMI-2: A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (clinicaltrials.gov) - Oct 29, 2024
P3, N=1000, Not yet recruiting, Sponsor: Janssen Research & Development, LLC
- || Enrollment closed, Trial completion date, Trial primary completion date: A Study Evaluating the Safety and Efficacy of Targeted Therapies in Subpopulations of Patients With Metastatic Colorectal Cancer (INTRINSIC) (clinicaltrials.gov) - Oct 28, 2024
P1, N=422, Active, not recruiting, Sponsor: Hoffmann-La Roche
Taken together, our studies have identified a unique pathway leading to chemoresistance and provide a rationale to combine FOLFOX with anti-PD-1/PD-L1 as an effective CRC treatment. Trial completion date: Apr 2026 --> Nov 2029 | Trial primary completion date: Sep 2025 --> Aug 2027 | Recruiting --> Active, not recruiting
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Trial primary completion date, Metastases: JANUS: Testing the Addition of an Anti-Cancer Drug, Irinotecan, to the Standard Chemotherapy Treatment (FOLFOX) After Long-Course Radiation Therapy for Advanced-Stage Rectal Cancers to Improve the Rate of Complete Response and Long-Term Rates of Organ Preservation (clinicaltrials.gov) - Oct 28, 2024
P2, N=312, Recruiting, Sponsor: Alliance for Clinical Trials in Oncology
Trial completion date: Apr 2026 --> Nov 2029 | Trial primary completion date: Sep 2025 --> Aug 2027 | Recruiting --> Active, not recruiting Trial primary completion date: Sep 2024 --> Sep 2025
- | NN1213 / Novo Nordisk
Trial completion, Trial completion date, Trial primary completion date: PACHA-01: Postoperative Hepatic Arterial Chemotherapy in High-risk Patients as Adjuvant Treatment After Resection of Colorectal Liver Metastases (clinicaltrials.gov) - Oct 27, 2024
P2/3, N=104, Completed, Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
Trial primary completion date: Sep 2024 --> Sep 2025 Suspended --> Completed | Trial completion date: May 2028 --> Mar 2024 | Trial primary completion date: May 2028 --> Mar 2024
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: PurIST Pancreatic Cancer Classifier: Analytic Validation of a 16-RNA Expression Signature Distinguishing Basal and Classical Subtypes. (Pubmed Central) - Oct 27, 2024
P2
The two major molecular subtypes of pancreatic adenocarcinoma reportedly have differential response to FOLFIRINOX-based therapy...In conclusion, the PurIST Pancreatic Cancer Classifier has robust performance to classify pancreatic adenocarcinoma into basal versus classical subtypes. Clinical validation studies are underway to evaluate outcome in patients whose standard-of-care chemotherapy regimen is selected based on rapid subtype assignment (NCT04683315).
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Journal: Tumor organoids improve mutation detection of pancreatic ductal adenocarcinoma. (Pubmed Central) - Oct 27, 2024
Moreover, eight cycles of FOLFIRINOX treatment did not significantly alter the mutational landscape at the DNA level, indicating the stability of the mutational profile after therapeutic pressure in patients...While they can reveal mutations that may be challenging to detect through traditional biopsy sequencing due to the inherently low tumor purity of PDAC, it is important to note that PDOs may not always fully recapitulate all mutations found in primary tumors. Despite this limitation, PDOs can still offer critical insights into the genomic complexities of PDAC, which is crucial for the development of personalized vaccines and therapies for this disease.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Biomarker, Journal: TGFB2 mRNA Levels Prognostically Interact with Interferon-Alpha Receptor Activation of IRF9 and IFI27, and an Immune Checkpoint LGALS9 to Impact Overall Survival in Pancreatic Ductal Adenocarcinoma. (Pubmed Central) - Oct 26, 2024
The treatment of pancreatic ductal adenocarcinoma (PDAC) is an unmet challenge, with the median overall survival rate remaining less than a year, even with the use of FOLFIRINOX-based therapies...The results of our study suggest that a combination of pharmacological tools can be used in treating PDAC patients, targeting both TGFB2 and the components of the type-I interferon signaling pathway. The significant statistical interaction between TGFB2 and the nine marker genes suggests that TGFB2 is a negative prognostic indicator at low levels of the IFN-I activated genes and TAM marker expression, including the immune checkpoint LGALS9 (upregulated 16.5-fold in tumor tissue; p < 0.0001).
- | leucovorin calcium / Generic mfg.
Journal, Metastases: NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI (Pubmed Central) - Oct 26, 2024
The significant statistical interaction between TGFB2 and the nine marker genes suggests that TGFB2 is a negative prognostic indicator at low levels of the IFN-I activated genes and TAM marker expression, including the immune checkpoint LGALS9 (upregulated 16.5-fold in tumor tissue; p < 0.0001). No abstract available
- | leucovorin calcium / Generic mfg.
Journal, Metastases: Reply to 'NALIRIFOX in the frontline for metastatic pancreatic cancer: evidence beyond NAPOLI (Pubmed Central) - Oct 26, 2024
No abstract available No abstract available
- | pyrimethamine / Generic mfg.
Journal: Long-Term Low-Dose Pyrimethamine Use for the Prevention of Ocular Toxoplasmosis Recurrences: A Cohort Study. (Pubmed Central) - Oct 25, 2024
Treatment was considered successful in 42 patients (84%). Long-term, low-dose pyrimethamine can be considered as a treatment option for the prevention of ocular toxoplasmosis recurrence in selected patients, with only a few, mild and reversible systemic adverse events.
- | Avastin (bevacizumab) / Roche
Retrospective data, Journal, Metastases: Impact on survival benefits of asymptomatic primary tumor resection after bevacizumab plus FOLFIRI as first-line therapy for patients with metastatic colorectal cancer with synchronous unresectable metastasis. (Pubmed Central) - Oct 25, 2024
Additionally, RT for primary tumor did not provide an additional OS benefit in mCRC with unresectable metastasis. A prospective randomized trial with a larger sample size is essential to further elucidate the role of PTR in this context.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg., irinotecan / Generic mfg.
Journal: Prognostic value of the TP53 mutation in patients with pancreatic ductal adenocarcinoma receiving FOLFIRINOX. (Pubmed Central) - Oct 25, 2024
PDAC patients with wild-type TP53 demonstrated longer OS than those with TP53 mutation, and this trend was intensified in patients with localized disease. This result may be due to an impaired response to FOLFIRINOX chemotherapy in patients with TP53 mutation.
- || Opdivo (nivolumab) / BMS
P1/2 data, Journal, PD(L)-1 Biomarker, IO biomarker, Metastases: Stereotactic Radiotherapy Plus Nivolumab in Patients with Locally Advanced Pancreatic Cancer: Results from Phase 1/2 Clinical CA209-9KH Trial. (Pubmed Central) - Oct 23, 2024
P1/2
SRT and nivolumab therapy exhibited manageable toxicity profiles consistent with previous findings; however, long-term treatment responses were not achieved with this regimen in locally advanced PDAC. Another strategy to trigger antitumor immunity in PDAC needs to be sought.
- | 5-fluorouracil / Generic mfg., leucovorin calcium / Generic mfg.
Biomarker, Journal, Tumor-infiltrating lymphocyte: The combination of CDX2 expression status and tumor-infiltrating lymphocyte density as a prognostic factor in adjuvant FOLFOX-treated patients with stage III colorectal cancers. (Pubmed Central) - Oct 23, 2024
Altogether, a high density of CD8 iTILs did not make a difference in the survival of patients with CRC with CDX2 loss. The combination of CDX2 expression and intraepithelial CD8 TIL density was an independent prognostic marker in adjuvant chemotherapy-treated patients with stage III CRC.
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Trial completion, Surgery, Metastases: ADORE: Adjuvant Chemotherapy After Preoperative Chemoradiotherapy to Treat Rectal Cancer (clinicaltrials.gov) - Oct 23, 2024
P2, N=322, Completed, Sponsor: Asan Medical Center
The combination of CDX2 expression and intraepithelial CD8 TIL density was an independent prognostic marker in adjuvant chemotherapy-treated patients with stage III CRC. Unknown status --> Completed
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Journal: A Case of Oropharyngeal Carcinoma Accompanying a Presacral Malignant Epidermoid Cyst. (Pubmed Central) - Oct 22, 2024
Postoperative treatment included chemotherapy (FOLFOX (5-FU, leucovorin, oxaliplatin)) and radiotherapy (50Gy/25Fr)...Metastatic mesopharyngeal carcinoma originating from other organs is extremely rare. While there is no established adjuvant chemotherapy regimen for presacral malignant epidermoid cysts, we preferred FOLFOX as used in the treatment of unresectable colorectal cancer with distant metastases.
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma
Trial completion date, Trial primary completion date, Metastases: Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 22, 2024
P3, N=400, Recruiting, Sponsor: Fudan University
While there is no established adjuvant chemotherapy regimen for presacral malignant epidermoid cysts, we preferred FOLFOX as used in the treatment of unresectable colorectal cancer with distant metastases. Trial completion date: Sep 2023 --> Dec 2025 | Trial primary completion date: Sep 2022 --> Dec 2025
- | Bylantra (devimistat) / Cornerstone Pharma, Ono Pharma
Journal, Metastases: Morphomics, Survival, and Metabolites in Patients With Metastatic Pancreatic Cancer. (Pubmed Central) - Oct 21, 2024
The latter 2 were associated with higher levels of animal product metabolism. These findings could represent novel focuses for prognostication and intervention to improve survival of patients with PDA.
- | Kaitanni (cadonilimab) / Akesobio
New P1/2 trial: AK104-IIT-C-M-0119: Cadonilimab Combination Regimen as First-line Treatment for HER2-expressing GC/GEJ Patients (clinicaltrials.gov) - Oct 21, 2024
P1/2, N=90, Recruiting, Sponsor: Zhejiang Cancer Hospital
- | 5-fluorouracil / Generic mfg., oxaliplatin / Generic mfg., leucovorin calcium / Generic mfg.
Journal, Metastases: An Active Trend of Immunotherapy Combination Regimen as Second-Line Therapy Towards Advanced Biliary Tract Cancer. (Pubmed Central) - Oct 18, 2024
The ICI combination strategy beyond first-line (L1) systemic chemotherapy plays a positive role in advanced BTCs. Both TKIs plus ICIs and chemotherapy plus ICIs could be considered candidates for trials and applied as competitive L2 treatment regimens for advanced BTCs in clinical practice.
- || osemitamab (TST001) / Transcenta
Enrollment closed, Trial primary completion date, Monotherapy: TransStar101: A Trial to Evaluate Safety and Tolerability of TST001 in Advanced or Metastatic Solid Tumors (clinicaltrials.gov) - Oct 18, 2024
P1/2, N=150, Active, not recruiting, Sponsor: Suzhou Transcenta Therapeutics Co., Ltd.
Both TKIs plus ICIs and chemotherapy plus ICIs could be considered candidates for trials and applied as competitive L2 treatment regimens for advanced BTCs in clinical practice. Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2024 --> Nov 2024
- || PD-L1.t-haNK / ImmunityBio, Anktiva (nogapendekin alfa inbakicept-pmln) / ImmunityBio
Trial completion date, Trial primary completion date, Metastases: QUILT-88: Combination Immunotherapy Plus Standard-of-Care Chemotherapy Versus Standard-of-Care Chemotherapy for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer (clinicaltrials.gov) - Oct 18, 2024
P2, N=328, Active, not recruiting, Sponsor: ImmunityBio, Inc.
Recruiting --> Active, not recruiting | Trial primary completion date: Jun 2024 --> Nov 2024 Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025
- | Avastin (bevacizumab) / Roche
Biomarker, Trial completion date, Trial primary completion date: Oxaliplatin, Leucovorin Calcium, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer (clinicaltrials.gov) - Oct 18, 2024
P3, N=3610, Active, not recruiting, Sponsor: National Cancer Institute (NCI)
Trial completion date: Oct 2024 --> Oct 2025 | Trial primary completion date: Oct 2024 --> Oct 2025 Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024
- |||| Vectibix (panitumumab) / Amgen, Lumakras (sotorasib) / Amgen, Mvasi (bevacizumab-awwb) / Daiichi Sankyo, Amgen, AbbVie
Trial completion date, Trial primary completion date: CodeBreaK 301: Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-na (clinicaltrials.gov) - Oct 18, 2024
P3, N=450, Recruiting, Sponsor: Amgen
Trial completion date: Sep 2024 --> Dec 2024 | Trial primary completion date: Sep 2024 --> Dec 2024 Trial completion date: Jan 2031 --> Apr 2031 | Trial primary completion date: Jun 2027 --> Sep 2027
- || Ziihera (zanidatamab-hrii) / Jazz
Trial primary completion date: ZWI-ZW25-201: A Safety and Efficacy Study of ZW25 (Zanidatamab) Plus Combination Chemotherapy in HER2-expressing Gastrointestinal Cancers, Including Gastroesophageal Adenocarcinoma, Biliary Tract Cancer, and Colorectal Cancer (clinicaltrials.gov) - Oct 17, 2024
P2, N=74, Active, not recruiting, Sponsor: Jazz Pharmaceuticals
Trial completion date: Jan 2031 --> Apr 2031 | Trial primary completion date: Jun 2027 --> Sep 2027 Trial primary completion date: Aug 2024 --> Jul 2025
- | Ariely (adebrelimab) / Jiangsu Hengrui Pharma, Lenvima (lenvatinib) / Eisai, Merck (MSD)
New P2 trial, Metastases: MA-ICC-II-006: Adebrelimab Combined with Irinotecan Liposomes, 5-FU, CF (clinicaltrials.gov) - Oct 17, 2024
P2, N=68, Not yet recruiting, Sponsor: Harbin Medical University
- ||| P2 data, P3 data, Retrospective data, Review, Journal, Surgery, Metastases: Induction treatment with FOLFIRINOX or oxaliplatin-based doublet followed by long-course chemoradiotherapy and surgery in locally advanced rectal cancer. A systematic review and pooled analysis from phase II and III trials. (Pubmed Central) - Oct 17, 2024
Induction with FOLFIRINOX showed better survival outcomes and pCR rates respect to CAPOX at the price of increased G3-4 neutropenia and nausea/vomiting. A randomized study comparing triplet and doublet chemotherapy in the frame of a total neoadjuvant treatment strategy is widely warranted.
- || Lumakras (sotorasib) / Amgen
Trial completion date, Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Oct 17, 2024
P1, N=1200, Recruiting, Sponsor: Amgen
A randomized study comparing triplet and doublet chemotherapy in the frame of a total neoadjuvant treatment strategy is widely warranted. Trial completion date: Jun 2029 --> Mar 2028 | Trial primary completion date: Jan 2027 --> Apr 2026
- | NN1213 / Novo Nordisk
Biomarker, Phase classification, Trial completion date, Trial primary completion date, Surgery: TRIGGER: Magnetic Resonance Tumour Regression Grade (mrTRG) as a Novel Biomarker - Phase III Non CTIMP Trial (clinicaltrials.gov) - Oct 17, 2024
P=N/A, N=441, Recruiting, Sponsor: Imperial College London
Trial completion date: Jun 2029 --> Mar 2028 | Trial primary completion date: Jan 2027 --> Apr 2026 Phase classification: P3 --> P=N/A | Trial completion date: Dec 2034 --> Dec 2036 | Trial primary completion date: Dec 2027 --> Dec 2026
- | 5-fluorouracil / Generic mfg.
Journal, Metastases: The Impact of Combined Chemotherapy and Intra-Tumoural Injection of Phosphorus-32 Microparticles on Vascularity in Locally Advanced Pancreatic Carcinoma. (Pubmed Central) - Oct 16, 2024
This is the first clinical study to demonstrate treatment-induced increased vascularity within pancreatic primary tumours, which followed 32P implantation and FOLFIRINOX chemotherapy. Larger comparative trials are warranted.
- | Kaitanni (cadonilimab) / Akesobio, Lenvima (lenvatinib) / Eisai, Merck (MSD)
Trial completion date: CCGLC-011: Combined HAIC, Lenvatinib and Cadonilimab As Conversion Therapy for Unresectable Hepatocellular Carcinoma (clinicaltrials.gov) - Oct 16, 2024
P2, N=36, Recruiting, Sponsor: Tongji Hospital
Larger comparative trials are warranted. Trial completion date: Jun 2026 --> Jun 2027
- | Avastin (bevacizumab) / Roche
New P2 trial: CRC-IIT-004: Evaluation of Irinotecan Liposome (II) Combined With 5-FU, LV, and Bevacizumab for mCRC (clinicaltrials.gov) - Oct 16, 2024
P2, N=30, Not yet recruiting, Sponsor: Affiliated Hospital of Nantong University
- ||| M9466 / EMD Serono
Enrollment open, Combination therapy, Metastases: M9466 in Combination With Topoisomerase 1 Inhibitors-based Regimens in Advanced Solid Tumors and Colorectal Cancer (DDRiver 511) (clinicaltrials.gov) - Oct 16, 2024
P1, N=54, Recruiting, Sponsor: EMD Serono Research & Development Institute, Inc.
Trial completion date: Jun 2026 --> Jun 2027 Not yet recruiting --> Recruiting
- | 5-fluorouracil / Generic mfg.
Trial completion date, Trial primary completion date, Metastases: INOVA-2024-27: Study of 5-fluorouracil (5-FU) in Patients With Metastatic Colorectal Cancer (clinicaltrials.gov) - Oct 16, 2024
P2, N=10, Not yet recruiting, Sponsor: Inova Health Care Services
Not yet recruiting --> Recruiting Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Apr 2025
- | Keytruda (pembrolizumab) / Merck (MSD)
Phase classification, Metastases: Safety and Efficacy of Pembrolizumab (MK-3475) Plus Binimetinib Alone or Pembrolizumab Plus Chemotherapy With or Without Binimetinib in Metastatic Colorectal Cancer (mCRC) Participants (MK-3475-651/KEYNOTE-651) (clinicaltrials.gov) - Oct 15, 2024
P1, N=116, Completed, Sponsor: Merck Sharp & Dohme LLC
Trial completion date: Feb 2025 --> Jun 2025 | Trial primary completion date: Dec 2024 --> Apr 2025 Phase classification: P1b --> P1
- || Lumakras (sotorasib) / Amgen
Trial completion date, Trial primary completion date, Monotherapy: CodeBreak101: Sotorasib Activity in Subjects With Advanced Solid Tumors With KRAS p.G12C Mutation (CodeBreak 101) (clinicaltrials.gov) - Oct 15, 2024
P1, N=1200, Recruiting, Sponsor: Amgen
Phase classification: P1b --> P1 Trial completion date: Mar 2028 --> Jun 2029 | Trial primary completion date: Sep 2025 --> Jan 2027